Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IDEAYA Biosciences ( (IDYA) ) has provided an update.
On January 12, 2026, IDEAYA Biosciences posted an updated corporate presentation for investors in connection with the JPM 2026 Annual Healthcare Conference, outlining its strategy to build a leading precision oncology franchise and detailing progress across its diversified clinical pipeline. The presentation highlighted a deep portfolio that includes darovasertib for uveal melanoma approaching a planned Phase 3 initiation in the first half of 2026, MTAP-pathway programs IDE397 and IDE892, antibody drug conjugate and DNA damage repair combinations such as IDE705 and IDE849, and next-generation agents targeting Werner helicase, KAT6/7, and other difficult-to-drug targets, underscoring IDEAYA’s intent to expand its reach across multiple solid tumor indications and strengthen its competitive position in precision oncology.
The most recent analyst rating on (IDYA) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences’ overall stock score reflects significant financial challenges and valuation concerns, primarily due to ongoing losses and a negative P/E ratio. The technical analysis shows some positive trends, but momentum is limited. The termination of the GSK collaboration adds uncertainty, although promising clinical data provides some optimism.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences is a precision medicine oncology company focused on developing targeted therapies for solid tumors, including uveal melanoma and cancers driven by DNA damage repair deficiencies and MTAP deletions. Leveraging an integrated discovery engine that combines physics- and AI-based drug design, CRISPR-based target and biomarker discovery, and structural biology, the company has advanced six internally discovered clinical-stage molecules across multiple first-in-class targets, with a pipeline that supports rational combinations, antibody drug conjugate and DNA damage repair combinations, and next-generation therapies in indications such as non-small cell lung cancer, colorectal, breast, and ovarian cancers.
Average Trading Volume: 1,046,757
Technical Sentiment Signal: Buy
Current Market Cap: $3.19B
See more insights into IDYA stock on TipRanks’ Stock Analysis page.